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Abstract
Background: Treatment of meniscus tears within the avascular region represents a significant challenge, particularly
in a situation of early osteoarthritis. Cell-based tissue engineering approaches have shown promising results. However,
studies have not found a consensus on the appropriate autologous cell source in a clinical situation, specifically in a
challenging degenerative environment. The present study sought to evaluate the appropriate cell source for
autologous meniscal repair in a demanding setting of early osteoarthritis.
Methods: A rabbit model was used to test autologous meniscal repair. Bone marrow and medial menisci were harvested
4 weeks prior to surgery. Bone marrow-derived mesenchymal stem cells (MSCs) and meniscal cells were isolated,
expanded, and seeded onto collagen-hyaluronan scaffolds before implantation. A punch defect model was performed on
the lateral meniscus and then a cell-seeded scaffold was press-fit into the defect. Following 6 or 12 weeks, gross joint
morphology and OARSI grade were assessed, and menisci were harvested for macroscopic, histological, and
immunohistochemical evaluation using a validated meniscus scoring system. In conjunction, human meniscal cells
isolated from non-repairable bucket handle tears and human MSCs were expanded and, using the pellet culture model,
assessed for their meniscus-like potential in a translational setting through collagen type I and II immunostaining, collagen
type II enzyme-linked immunosorbent assay (ELISA), and gene expression analysis.
Results: After resections of the medial menisci, all knees showed early osteoarthritic changes (average OARSI grade 3.1).
However, successful repair of meniscus punch defects was performed using either meniscal cells or MSCs. Gross joint
assessment demonstrated donor site morbidity for meniscal cell treatment. Furthermore, human MSCs had significantly
increased collagen type II gene expression and production compared to meniscal cells (p < 0.05).
Conclusions: The regenerative potential of the meniscus by an autologous cell-based tissue engineering approach was
shown even in a challenging setting of early osteoarthritis. Autologous MSCs and meniscal cells were found to have
improved meniscal healing in an animal model, thus demonstrating their feasibility in a clinical setting. However, donor
site morbidity, reduced availability, and reduced chondrogenic differentiation of human meniscal cells from debris of
meniscal tears favors autologous MSCs for clinical use for cell-based meniscus regeneration.
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Background
The meniscus is a tissue located between the femoral
condyle and tibial plateau of the knee and aids in the
force transmission, shock absorption, joint stability, lu-
brication, and proprioception of the knee joint [1]. The
meniscus is composed of two compartments: an inner
avascular region and a vascularized outer zone. The
composition of these regions varies, whereby the inner
meniscus resembles articular cartilage with predomin-
antly collagen type II and proteoglycans, whilst the outer
meniscus is similar to fibrocartilage with a high propor-
tion of collagen type I [2]. Meniscal tears are common
within the knee joint, particularly in sports and high-
impact trauma. The localization of the injury determines
the healing capacity of the meniscus. Lesions in the
vascularized zone have the ability to be successfully
repaired via suturing. However, tears within the avascu-
lar region have limited capacity for repair due to poor
intrinsic repair capacity [3]. Loss of meniscal substance
within this region overloads the underlying articular
cartilage [4], increasing the chances for early onset
osteoarthritis [5]. Methods for the treatment of meniscus
in a clinical situation have been described, including tis-
sue engineering approaches [6, 7]. However, there is no
consensus on the appropriate cell type to be utilized in
an autologous situation.
In a clinical situation, meniscal tears have been correlated
with the onset of early osteoarthritis [8, 9]. Due to delayed
diagnosis, many meniscal lesions have to be treated in an
environment with a disturbed joint homeostasis caused by
early degenerative changes. In such a situation additional
removal of meniscus tissue would only exacerbate the car-
tilage osteoarthritic state and lead to the collapse of the
knee joint [10]. Although regenerative treatment of the me-
niscus in such an early degenerative environment is de-
manding, the aim of restoration of as much meniscus tissue
as possible has to be proposed. Tissue engineered solutions
have the potential to naturally heal the defect and also to
protect the surrounding cartilage tissue from further
damage.
Tissue engineering approaches represent a novel
means for the regeneration of meniscal defects. These
may be placed into two categories: cell-based and cell
therapeutic approaches, with the former being the most
promising approach at present. Regenerative meniscus
treatment strategies provide a promising option, particu-
larly for treatment of critical defects in the avascular
region or even an early osteoarthritic situation. Recent
preclinical studies have shown promising results regard-
ing the regeneration of meniscal defects in the vascular
region but also in the avascular part using a previously
described approach [11–14].
However, as different cell sources have been used to en-
hance meniscal regeneration within these experimental
settings, it needs to be ascertained which cells provide the
best treatment for meniscus defects in the context of clin-
ical application. Meniscal cells may be isolated from the
tissue and then reinserted within a carrier back into the
patient. These cells have been evaluated in vitro, whilst
also demonstrating multilineage differentiation potential
[15–17]. However, there is a lack of in-vivo data concern-
ing the use of meniscal cells for tissue repair. Many trans-
lational studies have focused on the use of mesenchymal
stem cells (MSCs) due to their ability to differentiate
towards multiple lineages following extensive in-vitro
expansion. They have also been shown to have a high
chondrogenic potential under in-vitro conditions whilst
having the capacity to have a meniscus-like phenotype
[18]. Gonzalez-Fernandez et al. evaluated bone marrow-
or adipose-derived MSCs seeded into a collagen scaffold
and then inserted into a meniscus defect created within a
horse model [19]. Results demonstrated that there was no
difference in tissue regeneration 12 months postopera-
tively, agreeing with results from a previous investigation
[20]. MSCs have also been derived from the synovial fluid
and have been shown to increase following meniscal tears
[21]. Furthermore, investigators have used MSCs derived
from the synovial fluid and shown good outcomes in ani-
mal models 12 months postoperatively [22, 23].
The present study sought to evaluate, in a clinical situ-
ation, the feasibility of autologous cell-based tissue
engineering strategies for treating an avascular meniscus
defect in a knee with early degenerative changes. With
this aim, an early osteoarthritis situation was created by
resection of both medial menisci. A punch defect was
inserted in the avascular region of a rabbit lateral menis-
cus. Bone marrow and meniscus tissue were harvested
from the operated rabbit, and the cells were expanded
and reimplanted in the joint for assessment. In conjunc-
tion, human meniscal cells from nonrepairable bucket
tears and bone marrow cells were assessed with respect
to their meniscal potential under in-vitro conditions.
It was hypothesized that meniscus regeneration is also
possible in the environment of early osteoarthritis of the
knee. Both cell types, meniscal cells and MSCs, should
be capable of promoting meniscal healing in an animal
model within this demanding situation. However, donor
site morbidity and reduced potential of human meniscal
cells for chondrogenic differentiation might limit their
use at the injury site and favor a stem cell-based treat-
ment approach for meniscal defects in a clinical setting.
Methods
In-vivo model
Cell harvest and culture—animal trial
Bone marrow-derived autologous MSCs were harvested
approximately 4 weeks prior to meniscus defect treat-
ment. The bone marrow harvest and cell isolation were
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performed as previously described [24]. In brief, rabbits
were anesthetized intramuscularly using a combination
of 0.6 ml/kg ketamine 10% and xylazin 2%. The bone
marrow was harvested from the iliac crest via a small in-
cision into the bone cortex with an 18G needle and col-
lected into a syringe containing heparin. Culture media
was added to the aspirate and 20 × 106 nucleated cells
were plated into culture flasks and cultivated at 37 °C.
Dulbecco’s modified Eagle’s medium (DMEM) low glu-
cose concentration supplemented with 10% fetal bovine
serum (FBS), 1% penicillin, and 1% HEPES was added to
the aspirate. Following first refreshment after 7 days, ad-
herent cells were described as MSCs.
Meniscus cells were harvested from the complete
medial meniscus of both knees that were resected via
arthrotomy during the same surgery as the bone marrow
harvest. The menisci were minced and digested in colla-
genase solution overnight. Following centrifugation at
1000 rpm for 10 min, the cells were resuspended and
cultured with serum-supplemented RPMI-1640 (10%
FBS, 100 U/ml penicillin, 100 ug/ml streptomycin, 0.292
mg/ml L-glutamine, 2.383 mg/ml HEPES) at 37 °C and
5% CO2. Media changes for both cell types were carried
out twice a week. Cell harvest was performed when the
cultured cells had reached 80% confluence.
Surgical procedure for meniscus punch defects
Rabbit animal models have been described and are
validated models for testing of menisci treatment in
the avascular zone [11–13]. Similar to untreated hu-
man menisci, untreated defects in the avascular zone
or filling with a cell-free implant showed no tendency
for healing [11]. The procedures were approved by
the Institutional Animal Care and Use Committee at
our institution.
Twelve New Zealand White rabbits (5-month-old
males) were used in this study. The rabbits were anes-
thetized and exposure of the lateral joint compartment
was achieved by a lateral parapatellar arthrotomy. Using
limited soft tissue release, the lateral meniscus was
luxated anteriorly and avascular meniscal defects made
by using a 2-mm punch device (Stiefel, Offenbach am
Main, Germany).
On the one side, the punch defect was treated by an au-
tologous MSC matrix composite and, on the contralateral
knee, the punch defect in the lateral meniscus was filled
with an autologous meniscal cell matrix composite.
Fixation was achieved by press-fit implantation of the cell-
matrix constructs. Following relaxation of the meniscus,
the joint capsule was reattached and skin closure was
achieved. Postoperatively the animals were allowed free
movement without use of any immobilization.
The animals were sacrificed at 6 or 12 weeks; each
group consisted of 6 New Zealand White Rabbits.
Composite scaffolds/cell carrier and cell seeding
Sponge scaffolds were formulated as a cell carrier for the
study and manufactured from 70% derivatized hyaluronan-
ester and 30% gelatin, as previously described [25, 26]. The
hyaluronan component was obtained from the commercially
available product, Jaloskin (Fidia Advanced Biopolymers,
Abano Terme, Italy), which is manufactured from sodium
hyaluronate and highly esterified with benzyl alcohol on the
free carboxyl groups of glucoronic acid within the polymer.
The gelatin component was hydrolyzed bovine collagen
(Sigma, Taufkirchen, Germany). Porous scaffolds were
manufactured by solvent casting via a particulate leaching
technique, using NaCl with controlled grain size as the poro-
gen. The primary pore size was 250–350 μm and secondary
pore size was 50–100 μm. Scaffolds had a diameter of 2.2
mm and a height of 3 mm.
Cell loading of composite scaffolds
MSCs and meniscal cells were loaded onto the scaffolds
as previously described [13, 25]. Briefly, MSCs and
meniscal cells were trypsinized, counted, washed, and re-
suspended in DMEM-high glucose at a concentration of
1.0 × 106 cells into the composite scaffolds. The cell-
scaffold constructs were implanted in the meniscus
punch defects without preculture [11].
Gross assessment of joint morphology
Rabbits with surgical implants were euthanized for tissue
harvest with an overdose of pentobarbital (1600 mg/ml)
given intraperitoneally. Following exposure of the knee
joint, the macroscopic morphology of the meniscus and
the attachments of the meniscus to the tibial plateau and
the femoral condyles were evaluated and photographed.
Histology
The lateral menisci harvested from the in-vivo experi-
ments were fixed in 4% phosphate-buffered paraformal-
dehyde, embedded in Tissue-Tek OCT and frozen in
liquid nitrogen. Radial sections (10 μm) of all samples
were produced and stained with toluidine blue.
All distal femurs harvested from the in-vivo experi-
ments were prepared according to the OARSI histo-
logical cartilage pathology assessment protocol [27].
Samples were fixed for 24 h in 4% phosphate-buffered
saline (PBS)-buffered paraformaldehyde and then decal-
cified in 10% equivalent ethylenediaminetetraacetic acid
(Sigma, Taufkirchen, Germany) at pH 8. After decalcifi-
cation the femoral condyles were embedded, cut, and
stained with Safranin O (Sigma, Taufkirchen, Germany).
The grade of osteoarthritic change of all femoral
condyles was analyzed by the established OARSI grading
for osteoarthritis cartilage histopathology [27].
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Immunohistochemistry
As the pars intermedia of the rabbit meniscus contains
mainly collagen type II, specifically towards the avascular
central part of the meniscus, the immunohistochemical
analysis was performed for collagen type II. Sections were
washed and then digested for 15 min with 0.1% pepsin at
pH 3.5 to facilitate antibody access to the target epitopes.
Type II collagen was immunolocalized by the immunoper-
oxidase ABC technique (Vector, Burlingame, CA, USA),
applying monoclonal primary antibodies ms. anti-collagen
II, clone II-4C11 (Calbiochem, Merck, Schwalbach,
Germany), biotin-conjugated polyclonal secondary anti-
bodies (goat anti-mouse IgG; Jackson, West Grove, PA,
USA), and the nickel- and cobalt-enhanced DAB stain
visualization.
Meniscus scoring system
In order to compare the macroscopical, histological, and im-
munohistochemical results after repair of meniscal lesions, a
validated meniscus scoring system was used that was devel-
oped and published for the evaluation of meniscal defects
[11, 12, 28]. Subgroups in macroscopical assessment were
“stability” and “defect filling with repair tissue”; for histo-
logical analysis the “quality of the surface area”, “integration”,
“cellularity”, “cell morphology”; and for immunohistochemi-
cal characterization the “expression of proteoglycan and
moderate collagen type II in the repair tissue”. The repair
was graded by summing up the scores from 0–3 of eight in-
dividual subgroups. Consequently, the final scores were be-
tween 0 points (no repair) and maximal 24 points (complete
reconstitution of the meniscus). The data were collected
from two blinded scorers, both experienced in knee anatomy
of rabbits and in histological assessment.
In-vitro model
Cell harvest and aggregate preparation—human cells
The procedures were approved by the local Ethics Com-
mittee Review Board. Human meniscal specimens were
obtained, after written consent, from 14 patients (aver-
age age 36.6 years) undergoing arthroscopy of the knee
with the approval of the local Ethics Committee. If a
bucket handle tear of a meniscus was considered as non-
repairable, these meniscal parts were harvested for
further in-vitro analysis. Meniscal cells were isolated as
described in the in-vivo animal study. In all cases,
meniscal cells between passages 1 and 3 were used for
in-vitro assessments.
Human MSCs were extracted, after written consent, from
bone marrow samples of six patients (average age 32 years)
obtained through an iliac crest puncture prior to bone graft
harvest for back surgery. Initially, MSCs were isolated from
bone marrow aspirate by Ficoll density-gradient centrifuga-
tion. Cells were seeded in 75-cm2 tissue culture flasks and
maintained at 37 °C in a humidified atmosphere containing
5% CO2. Expansion medium consisted of DMEM (Gibco
Invitrogen, Karlsruhe, Germany) supplemented with 10%
FBS (PAN Biotech, Aidenbach, Germany) and 10% penicil-
lin/streptomycin (Gibco Invitrogen). During expansion the
medium was replaced twice a week.
Cell harvest was performed when the cultured menis-
cal cells or MSCs had reached 80% confluence. Aggre-
gates of the different cell types (2 × 105 cells/500 μl
medium) were centrifuged at 1000 rpm for 10 min and
then cultured in chondrogenic medium with serum-free
high-glucose DMEM (Gibco, Invitrogen) containing 100
nM dexamethasone (Sigma, Steinheim, Germany), 1%
ITS + 3 (insulin–transferrin–selenium solution; Sigma),
200 mM L-ascorbic acid 2-phosphate (Sigma), 1 mM so-
dium pyruvate (Gibco Invitrogen), and 10 ng/ml human
transforming growth factor (TGF) beta-1 (R&D Systems,
Wiesbaden, Germany) for 21 days. A total of 16 aggre-
gates of each cell source from each patient were ana-
lyzed at days 0, 7, 14, and 21.
Macroscopic evaluation and histology–human cells
Aggregates were fixed in 4% PBS-buffered paraformalde-
hyde and then infiltrated with increasing concentrations
(10–30%) of sucrose. Following photographic documen-
tation, aggregates were embedded in Tissue-Tek (Sakura,
Zoeterwoude, The Netherlands) and cryosectioned at
10–12 μm with an HM 500 OM cryotome (Microm,
Berlin, Germany). The metachromatic dye 1,9-dimethyl-
methylene blue (DMMB; Sigma) was used to detect and
analyze the synthesized sulfated glycosaminoglycans
(sGAG).
Immunohistochemistry (human collagen type I and II)
Sections were stained with monoclonal antibody against
type I and II collagen (mouse anti-type I collagen (1 ug/ml,
Calbiochem) or mouse anti-type II collagen IgG1 (1:100;
Calbiochem, Darmstadt, Germany)) after predigestion with
0.1% pepsin (Sigma) in 1× citric/phosphate McIlvaine buf-
fer (pH 3.6) for 15 min. Incubation with primary antibody
was carried out overnight at 4 °C. Biotinylated secondary
antibody (goat anti-mouse IgG at a dilution of 1:100) was
detected with a horseradish peroxidase (HRP)-labeled
avidin–biotin complex and diaminobenzidine tetrahydro-
chloride hydrate substrate.
Biochemical analyses
Aggregates were homogenized in 0.05 M acetic acid plus
0.5 M NaCl, digested with 10 mg/ml pepsin, and dissolved
in 0.05 M acetic acid on a rotator for 48 h at 4 °C. The
next steps of digestion were performed as described in the
Native Type II Collagen Detection Kit 6009 protocol
(Chondrex, Redmond, WA, USA).
The sGAG content of the digests was measured using a
colorimetric assay with DMMB. The amount of synthesized
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type II collagen of the aggregates was determined with the
Native Type II Collagen Detection Kit. In addition, the di-
gests were assayed for DNA concentration using the
Quant-iT dsDNA Assay Kit (Invitrogen, Eugene, OR,
USA).
RNA isolation, cDNA synthesis, and gene expression
analysis
Eight to ten aggregates per condition and time point (day 0
and day 21) for each donor were pooled and homogenized
using a precooled Precellys homogenizer with Precellys Cer-
amic Kit 1.4/2.8 mm. RNA was isolated with the RNeasy
Plus Universal Mini Kit (Qiagen) according to the manufac-
turer’s instructions. Reverse transcription was performed
with the Transcriptor First-Strand cDNA Synthesis kit
(Roche). Semiquantitative real-time polymerase chain reac-
tion (PCR) was performed with Brilliant SYBR Green QPCR
mix (Stratagene) on the Biorad CFX96 System. Gene expres-
sion was normalized to three different reference genes (vacu-
olar protein sorting 29 homolog (VPS29), proteasome
subunit beta type 4 (PSMB4), and receptor accessory protein
5 (REEP5)) using the delta-delta-Ct method. Primer
sequences were: PSMB4, forward gcttagcactggctgcttct,
reverse cgacatgcttggtgtagcct; VPS29, forward agctgg-
caaactgttgcac, reverse gacggtggtggtgactgag; REEP5, forward
aggtcagccactgggtatca, reverse cctctctcctctgcaacctg; col2, for-
ward gggcaatagcaggttcacgta, reverse tgtttcgtgcagccatcct
Statistical analysis
In-vitro human data were normalized and compared
using the two-tailed Mann-Whitney U test (SPSS 15.0
Software; SPSS, Chicago, IL, USA). In-vivo test scoring
results for the stem cell-treated groups and meniscal
cell-treated groups were compared by paired t tests. All
evaluations and levels of statistical significance were set
at a probability value of less than 0.05.
Results
Gross assessment of rabbit knee joints
To harvest a sufficient number of meniscal cells for the
cell-based treatment the total resection of both medial
menisci was necessary. Macroscopically, the gross as-
sessment of the rabbit knee joints revealed increasing
degenerative changes in all cases over time. Essentially,
after 3 months the medial compartments of the knees
showed early osteoarthritic changes with cartilage abra-
sion, chondral defects, and softening of the surrounding
cartilage. Small osteophytes were detected mainly in the
medial compartment (Fig. 1) as signs of early degenera-
tive changes.
Using the histological OARSI grading system all fem-
oral condyles showed moderate osteoarthritic signs with
Safranin O staining, with discontinuity or erosion of the
cartilage surface and vertical fissures extending to the
mid- or deep zone (Fig. 1). The average grading was 3.1,
indicating an early osteoarthritis situation.
In-vivo repair of meniscus punch defects by meniscal cell-
or MSC-based treatment
Six weeks after treatment of a meniscus punch defect by
implantation of a hyaluronan collagen composite matrix
seeded with autologous meniscal cells, the defects were
partially filled with undifferentiated tissue. Repair tissue
showed a lack of integration mainly towards the tip of
the meniscus. Three months after treatment, the menis-
cus punch defect in the avascular zone was completely
filled with repair tissue. Histologically, the defect was
filled with differentiated meniscus-like tissue. The de
novo repair tissue was totally integrated with the sur-
rounding native meniscus both at the base and also at
the tip of the meniscus. Immunohistochemistry also re-
vealed differentiation of the repair tissue with positive
staining for collagen II (Fig. 2a–h).
In comparison, meniscal punch defects treated with
MSCs showed partial defect filling with incomplete tissue
differentiation of the repair tissue after 6 weeks following
repair. After 3 months of treatment, meniscal defects were
completely filled with dense repair tissue with stable inte-
gration to the native meniscus. Histologically, the regener-
ated tissue was meniscus-like with a low cell density but
typical pericellular meniscal cavities and an extensive
amount of extracellular matrix. Immunostaining for colla-
gen II was moderately positive which is typical for rabbit
menisci in the pars intermedia. The reconstitution of
meniscus architecture with typically radially orientated
collagen fibers could be observed (Fig. 2i–p).
Scoring results of the meniscal repair tissue
Meniscal tissue regeneration induced by the different
cell-based repair strategies were compared and ana-
lyzed by a validated and published meniscus scoring
system. The scoring results for both groups were
high, particularly after 3 months, indicating good me-
niscus regeneration with differentiated tissue. Scoring
values between 12 and 16 points were observed. No
statistically significant difference between the meniscal
cell- and MSC-based treatments could be detected
after 6 weeks (P > 0.005) or 3 months (P > 0.005)
(Fig. 3).
Previous studies showed a reduced repair capacity for
untreated avascular meniscal defects or defects treated
by a cell-free scaffold in the same rabbit model. The
induced repair tissues in these situations demonstrated
poor quality with undifferentiated and nonintegrated fi-
brotic defect filling. The average score of the regenerated
defects in these historical controls remained at 8 points
after 6 weeks and showed no further changes after 3
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months [11]. Hence, a control with untreated or cell-free
scaffolds was not used in this study.
MSCs demonstrate greater chondrogenic potential
compared to meniscal cells
Passages 1–3 were required to achieve the necessary number
of cells from the arthroscopically resected native meniscus
tissue to create meniscal cell aggregates. Macroscopically and
histologically, no increase in size or chondrogenic differenti-
ation via DMMB and collagen II staining could be detected
over 21 days (Fig. 4), whilst collagen I was detected within
the matrix. Enzyme-linked immunosorbent assay (ELISA)
testing at day 0 revealed only a low amount of collagen II,
and no increase in collagen II normalized to DNA could be
Fig. 1 a Macroscopic view of femoral condyles 3 months after harvesting the medial meniscus showing early osteoarthritic changes: cartilage
degeneration (asterisk) and osteophyte formation (arrow) on the medial side are detectable. Scale bar = 5 mm. b Histological image of the
degenerated area of the femoral condyle showing early osteoarthritis changes. Scale bar = 2 mm. c Under higher magnification an OARSI grade 3
cartilage pathology with fissures extending into the deep zone can be observed. Scale bar = 0.2 mm. The average OARSI grading of all 12 knees
at 3 months was 3.1
Fig. 2 Macroscopic, histological, and immunohistochemical treatment results of 2-mm circular meniscus defects in the avascular zone with
meniscus cell-scaffold composites (a–h) and MSC-scaffold composites (i–p). In both groups (each n = 6), successful meniscus regeneration with
differentiated repair tissue could be detected after 3 months in vivo. Most of the treated menisci show promising treatment results (images a–d,
best results after meniscus cell treatment; i–l, best results after MSC treatment) with completely integrated meniscus-like regenerated tissue (e–h
and m–p show the worst results of each group). Scale bars: a,e,i,m = 4 mm, b,d,f,h,j,l,n,p = 0.5 mm, c,g,k,o = 0.1 mm). a,e,i,m Macroscopic view
of menisci on the tibia plateau with filled circular defects after 3 months; c,g,k,o Higher magnification of the integration zones of images b,f,j,n.
d,h,l,p Collagen type II immunostaining
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seen at days 7, 14, or 21 compared to day 0 (Fig. 5). Real--
time PCR revealed a moderate upregulation of collagen Type
II expression at day 21 (Fig. 6).
In comparison to meniscal cell aggregates, human
MSCs showed a macroscopic increase in size and chon-
drogenic differentiation in the DMMB or collagen type
II staining over 21 days (Fig. 4). Collagen type I could
only be detected at the surface of the MSC pellets after
21 days.
ELISA testing detected significantly (P < 0.005) higher
amounts of collagen II in MSC aggregates compared to
the meniscal cell pellets at all time points (days 0, 7, 14,
and 21) of culture and a fast and high increase in colla-
gen II content at days 7, 14, and 21 compared to day 0
(Fig. 5). In real-time PCR analysis, MSCs showed a sig-
nificantly (P < 0.005) higher upregulation of collagen
type II expression at day 21 compared to the meniscal
cell aggregates (Fig. 6).
These results indicate a significantly higher chondro-
genic potential of human MSCs compared to human
meniscal cells.
Discussion
Tissue engineering approaches for the treatment of
meniscal defects have demonstrated a promising means
of restoring native meniscus properties, especially injur-
ies to the inner avascular region. In particular, treatment
of meniscus injuries within the inner avascular region
could utilize this technique. However, to evaluate trans-
lational approaches, models mimicking the degenerative
situation are required. The present investigation sought
to evaluate cell-based tissue engineering approaches for
Fig. 3 Scoring results of the repair tissue quality after 6 weeks (n = 6 rabbits) and 3 months (n = 6 rabbits) in vivo. No statistical difference was
observed between the meniscal cell- and the MSC-treatment groups
Fig. 4 Representative macroscopic and histological images of cell aggregates of human meniscal cells (three pellets of each donor (n = 14)) from
non-refixable meniscal tears (upper row) and human mesenchymal stem cells (MSCs; three pellets of each donor (n = 6); lower row) at day 7 and
day 21. The meniscal cells show no increase in size and no chondrogenic differentiation from day 7 to day 21. No positive staining for collagen II
(Coll II) can be detected. Human MSC aggregates show an increase in size and chondrogenic differentiation during the culture period. At day 21
a positive staining for collagen II of the whole aggregate can be observed. Collagen I (Col I) staining was positive at the surface of the MSC
pellets. Scale bars: macroscopic images = 1 mm, histological images = 0.5 mm. DMMB 1,9-dimethylmethylene blue
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treatment of the avascular region of the meniscus within
a rabbit model showing signs of early osteoarthritis. The
present study demonstrated regenerative treatment of
avascular meniscal defects in this situation for two dif-
ferent autologous cell sources, meniscal cells and MSCs
that were seeded in a hyaluronan collagen composite
matrix. Three months of in-vivo treatment with either
cell type enabled defect filling with differentiated
meniscus-like tissue that was completely integrated with
the surrounding native tissue.
Early osteoarthritic changes of the knee are a very
demanding situation, especially for regenerative treat-
ment strategies [8]. Many of these degenerative
changes might initiate an inflammatory status and se-
cretion of catabolic factors that lead to development
of late-stage osteoarthritis [10]. In the context of early
osteoarthritis, significant correlations between early
osteoarthritic changes in the submeniscal tibial plat-
eau cartilage and meniscal degeneration have recently
been detected [29]. Additionally, there appears to be
a correlation between meniscal extrusion and cartilage
damage in the peripheral region of the tibial plateau,
underlining the fact that the submeniscal region is
vulnerable to early osteoarthritis [30], and thus leads
to structural and mechanical alterations of the menis-
cus leading to further implications within the joint
[31, 32]. Although the onset of joint degeneration
represents a very demanding situation for regenerative
treatment, these facts emphasize the need to restore
the meniscus to prevent knee collapse. Resections of
both medial menisci in the animal model in this
study leads to early degenerative changes in all rabbit
knees after 3 months, with cartilage defects and for-
mation of osteophytes. The average OARSI grading
was 3.1, indicating an early OA situation [27] (Fig. 1).
Meniscal cells are derived from the tissue at the defect
site and are a potential cell source for treatment of
meniscal injuries, although the meniscal self-healing
capacity is limited [1, 33]. Using a tissue engineering
approach helps to overcome these limitations, with a
reduced requirement for intrinsic meniscal regeneration.
The application of autologous meniscal cells seeded on a
hyaluronan collagen-based scaffold induced complete
defect filling with differentiated tissue. Webber [34]
Fig. 5 Comparison of collagen II (Col2) ELISA results of aggregates from human meniscal cells (black) (three pellets at each time point of each
patient (n = 14)) and mesenchymal stem cells (MSCs; gray) (three pellets at each time point of each patient (n = 6)) after 21 days of culture in
chondrogenic media. Meniscal cells from non-refixable meniscal tears show no chondrogenic potential. *P < 0.005
Fig. 6 Comparison of real-time PCR analysis for collagen type II (Col2)
expression of aggregates from human meniscal cells (black) (10 pellets at
each time point of each donor (n = 14)) and mesenchymal stem cells
(MSCs; gray) (eight pellets at each time point of each donor (n = 6)) after
21 days of culture in chondrogenic media. At day 21, MSCs showed a
significantly higher relative gene expression and collagen type II
upregulation compared to meniscal cells derived from non-refixable
meniscal tears. *P < 0.005
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showed that culture and differentiation of human menis-
cal cells was possible. However, monolayer expansion of
the cells has been shown to result in dedifferentiation
and thus requires three-dimensional culture to restore
phenotype [35]. Furthermore, regional differences
regarding the chondrogenic potential exist, as meniscal
cells derived from the outer vascularized zone show a
higher chondrogenic capacity than meniscal cells from
the inner avascular part [16]. Thus, meniscal cells alone
are not wholly responsible for the reduced intrinsic self-
healing capacity. Hennerbichler et al. [15] showed that
reinserted meniscal plugs in the outer and inner zones
of the meniscus reintegrated into the surrounding
meniscal tissue in vitro, with stable connecting fibers be-
tween the meniscal cells. Explants from the avascular
inner zone and vascular outer zone of the meniscus
exhibit similar healing potential and repair strength in
vitro. In the present investigation, we have shown the re-
pair capacity of the meniscus cells in an in-vivo
situation. The reason for the enhanced repair in these
previous investigations may be the existence of progeni-
tor populations within the meniscus, particularly from
the outer meniscus [1, 17].
A substantial disadvantage of autologous meniscal
cells as a source for cell-based treatment is their lim-
ited availability and the resultant donor-side morbid-
ity. In the in-vivo study, the resection of the medial
menisci of both knee joints was necessary to obtain a
sufficient number of cells for a cell-based treatment
of a small 2-mm circular punch defect. Three months
postoperatively, all knee joints began to show degen-
erative changes in the medial compartment with
chondral lesions, softening of the surrounding cartil-
age, and formation of osteophytes. This is not
surprising since the resection of the medial meniscus
serves as a model for inducing the development of
osteoarthritis in animal studies [36]. In clinical
practice, the only possible option to obtain autologous
meniscal cells would be to harvest meniscal debris or
tissue derived from nonrepairable tears. Baker et al.
described that cells derived from surgical debris are a
potent cell source for engineered meniscus constructs
in vitro [37]. However, their results are dependent
upon two observations. Their use of a biodegradable
nanofibrous scaffold contributed to the increasing
content of proteoglycan and collagen II over the
culture period of 70 days. Furthermore, some of the
donors came from knee arthroplasty patients, and
thus there were resections with large amounts of me-
niscus substance. Nevertheless, there was significant
data variation relating to these observations and the
continual passaging of meniscal cells increases the
risk of cell dedifferentiation to obtain sufficient cell
numbers for further culture and analysis.
In the present study, an in-vitro evaluation of human
meniscal tissue from non-refixable tears was used to
assess their potential in a clinical setting. However, the
human meniscal cell pellets cultured in chondrogenic
medium revealed moderate gene expression and no
deposition of collagen II after 21 days (Figs. 4, 5 and 6).
As previously discussed, monolayer expansion to achieve
sufficient cell numbers for aggregate formation increases
dedifferentiation and may have led to poor outcomes in
vitro despite the presence of TGF-β. These results are
also contrary to our in-vivo data or similar studies using
meniscus tissue, and thus indicate that this may not be
an appropriate cell source for meniscus repair in a
clinical setting.
An alternative cell source for meniscus repair are
MSCs, and these have been shown to induce meniscus
regeneration [11–13, 28]. MSCs have been detected in
vivo following meniscal lesions in the knee synovial fluid
[21], whilst a progenitor population has been identified
within the avascular region of the injured meniscus that
had high migratory potential towards the lesion [38].
However, our study focused on the MSCs derived from
the bone marrow, which show the potential to differenti-
ate into bone, adipose tissue, and cartilage in this setting
[13]. These cells demonstrated meniscus-like repair in
the punch defect after 3 months in vivo. This confirms
the results of previously published studies on different
meniscus defect types that all showed that untreated in-
juries showed no healing, with a “non-union” of the le-
sion comparable to the human situation [11–13, 28].
Furthermore, in these studies, the application of a MSC-
based treatment revealed significantly superior results
compared to the use of a cell-free scaffold. Therefore,
the described animal model can be considered as appro-
priate for the evaluation of the regenerative potential of
different meniscus treatment options. As the historical
controls with untreated defects and treatment with cell-
free scaffolds showed only a reduced quality of regener-
ation with nonintegrated fibrous tissue, different cell-
based repair strategies should be tested in this study.
Meniscal cells and MSCs differentiated and integrated
meniscus-like repair tissue, with scoring results between
12 and 16 points after 3 months. In comparison, the
historical controls of cell-free treatment showed scoring
results of only 8 points, indicating an improvement in
meniscus regeneration using a cell-based repair strategy.
In addition, the demanding early osteoarthritis situation
within the model provides further evidence of the suit-
ability of MSCs within a clinical context.
Previous studies have reported the positive effects of
MSCs on meniscus regeneration both in vitro and in
vivo and from different sources, including adipose and
synovium [18, 39, 40]. Gonzalez-Fernandez et al. com-
pared the regeneration potential induced by bone
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marrow-derived MSCs to adipose tissue-derived stem
cells in an equine model and found no differences
between the two cell sources [19]. As previously stated,
the feasibility within a degenerative situation was not
assessed in their equine model. The reasons for the
successful repair of the meniscus using MSCs may be
related to two distinct mechanisms. MSCs may have
differentiated into meniscal cells due to the surrounding
tissue matrix, and cell-cell communication or the secre-
tion of trophic factors released by MSCs may have
helped to heal the meniscus via pharmacological means
or via recruitment of resident cell populations [41].
As MSCs from many sources show positive results
regarding the enhancement of meniscal repair it
seems that the question is not the origin of the
progenitor cells but more their availability and ap-
plicability for clinical use. In other connective tis-
sues, such as articular cartilage, preliminary clinical
data show positive effects on regeneration with the
application of MSCs. Sekiya et al. detected signifi-
cant improvements after arthroscopic transplantation
of synovial-derived stem cells in small (average 200
mm2) cartilage defects by magnetic resonance im-
aging (MRI) scoring, qualitative histology, and
Lysholm score evaluation [42]. A further advantage
of autologous MSCs is the potential for a single-step
cell-based repair augmentation since they have a
higher proliferation rate than meniscal cells and are
less susceptible to dedifferentiation [43]. Our in-vitro
results confirm the high chondrogenic potential of
human MSCs and their qualification for augmenta-
tion of meniscal healing in a clinical setting.
However, limited data are available on the clinical use
of MSCs for meniscus regeneration. Whitehouse et al.
[44] conducted an open-label first-in-human study for
repair of avascular meniscal lesions with autologous
MSCs. Following isolation and expansion, MSCs from
iliac crest bone marrow were seeded on collagen
scaffolds. These cell-matrix constructs were placed and
sutured into avascular meniscal tears of five patients.
After 2 years, three patients were asymptomatic with no
signs of a recurrent tear in the MRI control compared to
two patients that required subsequent meniscectomy
due to re-tear or nonhealing. In a controlled randomized
trial, Vangsness et al. delivered allogenic MSCs 1 week
after arthroscopic partial medial meniscectomy via intra-
articular injection to the knee. A year after surgery, a
significantly increased meniscal volume determined by
quantitative MRI was detected in 24% of patients in the
treatment group, while no patient in the control group
showed an increasing amount of meniscus tissue. Add-
itionally, stem cell injection revealed beneficial effects on
pain management of these patients after partial menisc-
ectomy [45].
A limitation of this study is the animal model and the
comparison to a historical control. However, the study
shows that regeneration of avascular meniscal defects is
possible by a cell-based treatment even in a demanding
and clinically very relevant situation such as early osteo-
arthritis. A strength of the study is the analysis of differ-
ent human cell sources that may be used for an
autologous cell-based meniscus treatment using menis-
cus cells or MSCs. In comparison to MSCs, human
meniscal cells from non-refixable meniscal tears or
meniscal debris demonstrated a very limited capacity for
chondrogenic differentiation. Thus, MSCs appear to be
the most promising cell source for an autologous cell-
based meniscus treatment approach, including low
donor site morbidity. However, there are disadvantages
that limit their clinical applicability, particularly the high
treatment costs, requirement for cell expansion prior to
application, and regulatory burdens that currently inhibit
their use in daily clinical practice [43]. These problems
should be resolved to facilitate the cell-based treatment
of meniscal defects with MSCs and therefore improve
the clinical outcome of this common injury.
Conclusions
Cell-based treatment of meniscal defects with autolo-
gous meniscal cells and MSCs showed equally positive
effects on meniscus regeneration in an animal model in
a situation of early osteoarthritis. The defects were com-
pletely filled with differentiated meniscus-like tissue in
both groups. However, meniscal cell harvest revealed
inacceptable donor side morbidity causing the early
osteoarthritic changes. Additionally, human meniscal
cells derived from nonrepairable meniscal tears showed
no chondrogenic potential using ELISA and real-time
PCR analysis. In contrast, due to their high regenerative
capability and promotion of meniscal healing, MSCs ap-
pear to be a more appropriate source for cell-based
treatment of the meniscus in a clinical setting of early
osteoarthritis.
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